US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco S&P Spin-Off ETF

81.01

-0.4200-0.52%

Post-market: 80.74-0.2717-0.34%16:05 EDT

Volume:1.32K

Turnover:107.00K

Market Cap:67.24M

PE:112.52

High:81.01

Open:80.79

Low:80.74

Close:81.43

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSD\",,,,,undefined,":{"symbol":"CSD","market":"US","secType":"STK","nameCN":"Invesco S&P Spin-Off ETF","latestPrice":81.0118,"timestamp":1747771200000,"preClose":81.4318,"halted":0,"volume":1323,"hourTrading":{"tag":"盘后","latestPrice":80.7401,"preClose":81.0118,"latestTime":"16:05 EDT","volume":3,"amount":243.0354,"timestamp":1747771511817},"delay":0,"floatShares":830000,"shares":830000,"eps":0.72,"marketStatus":"Not Yet Opened","change":-0.42,"latestTime":"05-20 16:00:00 EDT","open":80.79,"high":81.0118,"low":80.7401,"amount":106998.1595,"amplitude":0.003337,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.72,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747814400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":81.4318,"sharesOutstanding":830000,"nav":81.42451,"aum":67582343.3,"dividendRate":0.001728,"bidAskSpread":0.002,"postHourTrading":{"tag":"盘后","latestPrice":80.7401,"preClose":81.0118,"latestTime":"16:05 EDT","volume":3,"amount":243.0354,"timestamp":1747771511817},"volumeRatio":0.774862,"impliedVol":0.0368,"impliedVolPercentile":0.0763},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSD\",,,,,undefined,":{"symbol":"CSD","floatShares":830000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.774862,"shares":830000,"dividePrice":0.14,"high":81.0118,"amplitude":0.003337,"preClose":81.4318,"low":80.7401,"week52Low":63.06,"pbRate":"--","week52High":93.6,"institutionHeld":0,"latestPrice":81.0118,"eps":0.72,"divideRate":0.001728,"volume":1323,"delay":0,"ttmEps":0.72,"open":80.79,"prevYearClose":82.16,"prevWeekClose":81.4291,"prevMonthClose":73.4881,"prevQuarterClose":75.0195,"fiveDayClose":80.837,"twentyDayClose":67.9466,"sixtyDayClose":81.6646},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CSD\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535108870","title":"Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108870?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:09","pubTimestamp":1747339740,"startTime":"0","endTime":"0","summary":"RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis  initiated with topline interim data expected in the first half of 2026. Two abstracts accepted to the American Thoracic Society  2025 International Conference. Cash runway extended following previously announced warrant transactions and private placement. \"Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF,\" said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. \"We have taken several strategic steps to prepare for this trial. Our LTI-03 program continues to evolve as we entered into a collaboration with Qureight to bring cutting-edge technology to our imaging and data analysis and obtained patents covering our novel formulation and administration methods. We are committed to continuing this momentum of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","ATS","RNTX","LENZ","BK4139","BK4161","CSD"],"gpt_icon":0},{"id":"2532075868","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075868","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075868?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis .Dr. Muhunthan Thillai, Chief Executive Officer of Qureight, said, \"We're delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNTX","CSD","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSD","BK4161","LENZ","AFG","ATS","BK4139","BK4007","BK4117","BK4107","RNTX"],"gpt_icon":0},{"id":"2527991034","title":"Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2527991034","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527991034?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis . AUSTIN, Texas, April 15, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis  in the peer-reviewed journal, Biomedicines.Rein Therapeuticsis a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSD","BK4139","BK4007","LENZ","RNTX"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSD\",params:#limit:5,,,undefined,":[{"date":"2024-12-23","symbol":"CSD","amount":0.13729,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P Spin-Off ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"},{"date":"2023-12-18","symbol":"CSD","amount":0.33167,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"Invesco S&P Spin-Off ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"CSD","amount":0.45,"defaultRemindTime":1671460200000,"name":"Invesco S&P Spin-Off ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"CSD","amount":0.4547,"defaultRemindTime":1640010600000,"name":"Guggenheim Spin-Off ETF","recordDate":"2021-12-31","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000},{"market":"US","date":"2020-12-21","symbol":"CSD","amount":0.54891,"name":"Guggenheim Spin-Off ETF","recordDate":"2020-12-31","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSD\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-24","recordDate":"2015-12-29","paymentDate":"2015-12-31","value":1.0016,"currency":"USD"},{"executeDate":"2016-12-23","recordDate":"2016-12-28","paymentDate":"2016-12-30","value":0.702,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-31","value":0.54659,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-31","value":0.54891,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.4547,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSD\",market:\"US\",delay:false,,,undefined,":{}}}